<MedlineCitation Status="Completed">
<MedlineID>10011239</MedlineID>
<PMID>154344</PMID>
<DateCreated>
<Year>1979</Year>
<Month>05</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>1979</Year>
<Month>05</Month>
<Day>16</Day>
</DateCompleted>
<DateRevised>
<Year>2000</Year>
<Month>12</Month>
<Day>18</Day>
</DateRevised>
<Article>
<Journal>
<ISSN>0006-2960</ISSN>
<JournalIssue>
<Volume>18</Volume>
<Issue>1</Issue>
<PubDate>
<Year>1979</Year>
<Month>Jan</Month>
<Day>9</Day>
</PubDate>
</JournalIssue>
</Journal>
<ArticleTitle>Inhibition of the (Ca2+)ATPase from sarcoplasmic reticulum by dicyclohexylcarbodiimide: evidence for location of the Ca2+ binding site in a hydrophobic region.</ArticleTitle>
<Pagination>
<MedlinePgn>108-13</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Dicyclohexylcarbodiimide (DCCD) inhibits the (Ca2+)ATPase, Ca2+ uptake by sarcoplasmic reticulum vesicles and Ca2+ binding to the (Ca2+)ATPase from sarcoplasmic reticulum. Ca2+ (at micron concentrations) specifically protects against DCCD inhibition. The inhibition can, therefore, be readily demonstrated only in the presence of Ca2+ chelating agents such as EGTA. In the presence of EGTA, the ionophore A-23187 increased the sensitivity to DCCD. The ionophore also increased the phosphorylation of the enzyme by inorganic phosphate in the presence of Mg2+. These results indicate that tightly bound Ca2+ is located in a hydrophobic region of the enzyme which is not accessible to EGTA. Complete inhibition of the (Ca2+)ATPase is accompanied by binding of 4--5 nmol of [14C]DCCD per mg of ATPase protein in the absence of Ca2+ compared with 2 nmol bound per mg in the presence of Ca2+ with no ATPase inhibition. Assuming a molecular weight of 100 000 for the ATPase monomer, about 1 nmol of DCCD inhibits 4 nmol of ATPase. This result suggests that the minimal functional unit of the enzyme is a tetramer. Following trypsin digestion of the [14C]DCCD-labeled ATPase most of the radioactivity appears in the 20 000-dalton fragment. We propose that DCCD reacts with the Ca2+-binding site of the ATPase.</AbstractText>
</Abstract>
<AuthorList>
<Author>
<LastName>Pick</LastName>
<ForeName>U</ForeName>
<Initials>U</Initials>
</Author>
<Author>
<LastName>Racker</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>UNITED STATES</Country>
<MedlineTA>Biochemistry</MedlineTA>
<NlmUniqueID>0370623</NlmUniqueID>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Carbodiimides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Peptide Fragments</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>538-75-0</RegistryNumber>
<NameOfSubstance>Dicyclohexylcarbodiimide</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>67-42-5</RegistryNumber>
<NameOfSubstance>Egtazic Acid</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>7440-70-2</RegistryNumber>
<NameOfSubstance>Calcium</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.21.4</RegistryNumber>
<NameOfSubstance>Trypsin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.1.38</RegistryNumber>
<NameOfSubstance>Ca(2+)-Transporting ATPase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName>Animal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Binding Sites</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Ca(2+)-Transporting ATPase</DescriptorName>
<QualifierName MajorTopicYN="Y">antagonists &#38; inhibitors</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Calcium</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Carbodiimides</DescriptorName>
<QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Dicyclohexylcarbodiimide</DescriptorName>
<QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Egtazic Acid</DescriptorName>
<QualifierName>pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Kinetics</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Peptide Fragments</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Protein Binding</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Sarcoplasmic Reticulum</DescriptorName>
<QualifierName MajorTopicYN="Y">enzymology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Support, U.S. Gov't, Non-P.H.S.</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Support, U.S. Gov't, P.H.S.</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Trypsin</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
